Korean J Radiol.
2022 Jul;23(7):773-774. 10.3348/kjr.2022.0110.
Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible
- Affiliations
-
- 1Neurology & Neurophysiology Center, Vienna, Austria
- KMID: 2530762
- DOI: http://doi.org/10.3348/kjr.2022.0110
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
- Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination: A Case Report
- New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review
- Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
- Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
